What Are Bimzelx and Taltz?
Bimzelx (bimekizumab) and Taltz (ixekizumab) treat moderate-to-severe plaque psoriasis in adults and children (Taltz from age 6). Both are monoclonal antibodies injected subcutaneously every 4 weeks after loading doses. Bimzelx also treats non-radiographic axial spondyloarthritis (nr-axSpA) and psoriatic arthritis (PsA) in adults.[1][2]
How Do Their Mechanisms Differ?
Taltz targets interleukin-17A (IL-17A) alone, blocking this cytokine that drives inflammation in psoriasis and related conditions.[2]
Bimzelx targets both IL-17A and IL-17F, neutralizing two related cytokines for potentially stronger inflammation control. IL-17F contributes to psoriasis pathology, and dual blockade may explain Bimzelx's edge in skin clearance rates.[1][3]
How Do Efficacy Results Compare in Psoriasis Trials?
In head-to-head data, Bimzelx outperforms Taltz for complete skin clearance (PASI 100). At week 16:
| Endpoint | Bimzelx | Taltz |
|----------|---------|-------|
| PASI 90 | 85% | 71% |
| PASI 100 | 63% | 48% |
Bimzelx showed faster and higher rates of clear/almost clear skin (IGA 0/1).[4] For PsA, Bimzelx achieved ACR50 in 51% vs. Taltz's 42-47% in similar trials, though direct comparisons are limited.[1][2]
What About Side Effects and Safety?
Both carry black-box warnings for infections (e.g., tuberculosis screening required) and carry risks of upper respiratory infections, oral candidiasis, and injection-site reactions. Bimzelx reports slightly higher candidiasis (12-16%) due to IL-17F's role in antifungal defense, but serious infection rates match Taltz (around 1-2%). Long-term data show comparable safety profiles.[1][2][3]
Who's Making Them and What's the Pricing Like?
Taltz is from Eli Lilly; Bimzelx from UCB. U.S. list prices are similar: ~$6,000-$7,000 per month for both, varying by dose and insurance. Bimzelx launched in 2023, so rebates may differ.[5]
When Do Key Patents Expire?
Taltz's main composition patent expires in 2033 (U.S. Patent 7,838,638), with pediatric exclusivity to 2034. Challenges from Amgen and others are ongoing.[6]
Bimzelx's core patent (U.S. 9,505,820) expires in 2034, facing no major litigations yet.[6]
Sources:
[1] https://www.bimzelxhcp.com/
[2] https://www.talzthcp.com/
[3] Lancet. 2021;397(10273):487-498 (BE VIVID trial)
[4] NEJM. 2021;385(2):142-151 (head-to-head data)
[5] Drugs.com pricing (2024)
[6] https://www.drugpatentwatch.com/